Design and created by Guideline Central in participation with the International Society of Oral Oncology and Multinational Association of Supportive Care in Cancer.
Multinational Association of Supportive Care in Cancer
International Society of Oral Oncology
Publication Date: Jul 25, 2024
Page Last Updated: May 5, 2026
Raber-Durlacher JE, Treister NS, Zadik Y, Dean DR, Miranda-Silva W, Fregnani ER, Epstein JB, Elad S. MASCC/ISOO Clinical Practice Statement: The risk of secondary oral cancer following hematopoietic cell transplantation. Support Care Cancer. 2024 Jul 25;32(8):545. doi: 10.1007/s00520-024-08685-y. PMID: 39048762; PMCID: PMC11269467.
A MASCC/ISOO Clinical Practice Statement (CPS) is aimed at generating a concise tool for clinicians that concentrates practical information needed for the management of oral complications of cancer patients. This CPS is focused on the risk of secondary oral cancer following hematopoietic cell transplantation (HCT).
D018380 - Hematopoietic Stem Cell Transplantation
D018380 - Hematopoietic Stem Cell Transplantation
Guideline Central and select third party use “cookies” on this website to enhance the user experience.
This technology helps us gather statistical and analytical information to optimize the relevant content for you.
The user also has the option to opt-out which may have an effect on the browsing experience.